M. Chamberlain, L. Junck, and D. Brandsma, Leptomeningeal metastases: a RANO proposal for response criteria, Neuro Oncol, vol.19, pp.484-492, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02940579

H. Rudnicka, A. Niwi-nska, and M. Murawska, Breast cancer leptomeningeal metastasis-the role of multimodality treatment, J Neurooncol, vol.84, pp.57-62, 2007.

H. Gauthier, M. N. Guilhaume, and F. C. Bidard, Survival of breast cancer patients with meningeal carcinomatosis, Ann Oncol, vol.21, pp.2183-2187, 2010.

S. Lee, H. K. Ahn, and Y. H. Park, Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations, Breast Cancer Res Treat, vol.129, pp.809-817, 2011.

C. R. De-azevedo, M. R. Cruz, and L. T. Chinen, Meningeal carcinomatosis in breast cancer: prognostic factors and outcome, J Neurooncol, vol.104, pp.565-572, 2011.

F. Lara-medina, A. Crismatt, and C. Villarreal-garza, Clinical features and prognostic factors in patients with carcinomatous meningitis secondary to breast cancer, Breast J, vol.18, pp.233-241, 2012.

I. Meattini, L. Livi, and C. Saieva, Prognostic factors and clinical features in patients with leptominengeal metastases from breast cancer: a single center experience, J Chemother, vol.24, pp.279-284, 2012.

H. J. Kim, S. A. Im, and B. Keam, Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment, J Neurooncol, vol.106, pp.303-313, 2012.

A. Niwi-nska, H. Rudnicka, and M. Murawska, Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survival, Med Oncol, vol.30, p.408, 2013.

S. Yust-katz, P. Garciarena, and D. Liu, Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis, J Neurooncol, vol.114, pp.229-235, 2013.

E. Le-rhun, S. Taillibert, and F. Zairi, A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer, J Neurooncol, vol.113, pp.83-92, 2013.

A. Niwi-nska, H. Rudnicka, and M. Murawska, Breast cancer leptomeningeal metastasis: the results of combined treatment and the comparison of methotrexate and liposomal cytarabine as intra-cerebrospinal fluid chemotherapy, Clin Breast Cancer, vol.15, pp.66-72, 2015.

P. G. Morris, A. S. Reiner, and O. R. Szenberg, Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy, J Thorac Oncol, vol.7, pp.382-385, 2012.

J. H. Park, Y. J. Kim, and J. O. Lee, Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era, Lung Cancer, vol.76, pp.387-392, 2012.

H. S. Gwak, J. Joo, and S. Kim, Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer, J Thorac Oncol, vol.8, pp.599-605, 2013.

S. J. Lee, J. I. Lee, and D. H. Nam, Leptomeningeal carcinomatosis in nonsmall-cell lung cancer patients: impact on survival and correlated prognostic factors, J Thorac Oncol, vol.8, pp.185-191, 2013.

J. W. Riess, S. Nagpal, and M. Iv, Prolonged survival of patients with nonsmall-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era, Clin Lung Cancer, vol.15, pp.202-206, 2014.

J. L. Kuiper, L. E. Hendriks, and A. J. Van-der-wekken, Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: a retrospective cohort analysis, Lung Cancer, vol.89, pp.255-261, 2015.

L. Harstad, K. R. Hess, and M. D. Groves, Prognostic factors and outcomes in patients with leptomeningeal melanomatosis, Neuro Oncol, vol.10, pp.1010-1018, 2008.

M. H. Geukes-foppen, D. Brandsma, and C. U. Blank, Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma, Ann Oncol, vol.27, pp.1138-1142, 2016.

R. Roelz, P. Reinacher, and R. Jabbarli, Surgical ventricular entry is a key risk factor for leptomeningeal metastasis of high grade gliomas, Sci Rep, vol.5, p.17758, 2015.

J. H. Ahn, S. H. Lee, and S. Kim, Risk for leptomeningeal seeding after resection for brain metastases: implication of tumor location with mode of resection, J Neurosurg, vol.116, pp.984-993, 2012.

J. P. Elliott, G. E. Keles, and M. Waite, Ventricular entry during resection of malignant gliomas: effect on intracranial cerebrospinal fluid tumor dissemination, J Neurosurg, vol.80, pp.834-839, 1994.

L. K. Norris, S. A. Grossman, and A. Olivi, Neoplastic meningitis following surgical resection of isolated cerebellar metastasis: a potentially preventable complication, J Neurooncol, vol.32, pp.215-223, 1997.

T. C. Van-der-ree, D. W. Dippel, and C. J. Avezaat, Leptomeningeal metastasis after surgical resection of brain metastases, J Neurol Neurosurg Psychiatry, vol.66, pp.225-227, 1999.

D. Suki, M. A. Hatiboglu, and A. J. Patel, Comparative risk of leptomeningeal dissemination of cancer after surgery or stereotactic radiosurgery for a single supratentorial solid tumor metastasis, Neurosurgery, vol.64, pp.674-676, 2009.

M. D. Johnson, V. Avkshtol, and A. M. Baschnagel, Surgical resection of brain metastases and the risk of leptomeningeal recurrence in patients treated with stereotactic radiosurgery, Int J Radiat Oncol Biol Phys, vol.94, pp.537-543, 2016.

S. Abouharb, J. Ensor, and M. E. Loghin, Leptomeningeal disease and breast cancer: the importance of tumor subtype, Breast Cancer Res Treat, vol.146, pp.477-486, 2014.

B. C. Liao, J. H. Lee, and C. C. Lin, Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis, J Thorac Oncol, vol.10, pp.1754-1761, 2015.

S. Matsumoto, K. Takahashi, and R. Iwakawa, Frequent EGFR mutations in brain metastases of lung adenocarcinoma, Int J Cancer, vol.119, pp.1491-1494, 2006.

T. Iuchi, M. Shingyoji, and M. Itakura, Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations, Int J Clin Oncol, vol.20, pp.674-679, 2015.

J. F. Gainor, S. H. Ou, and J. Logan, The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer, J Thorac Oncol, vol.8, pp.1570-1573, 2013.

D. W. Lee, K. H. Lee, J. W. Kim, and B. Keam, Molecular targeted therapies for the treatment of leptomeningeal carcinomatosis: current evidence and future directions, Int J Mol Sci, vol.17, p.1074, 2016.

A. T. Shaw, D. W. Kim, and K. Nakagawa, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med, vol.368, pp.2385-2394, 2013.

J. L. Clarke, H. R. Perez, and L. M. Jacks, Leptomeningeal metastases in the MRI era, Neurology, vol.74, pp.1449-1454, 2010.

K. Oechsle, V. Lange-brock, and A. Kruell, Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis, J Cancer Res Clin Oncol, vol.136, pp.1729-1735, 2010.

U. Herrlinger, H. Wiendl, and M. Renninger, Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value, Br J Cancer, vol.91, pp.219-224, 2004.

F. Clatot, G. Philippin-lauridant, and M. J. Ouvrier, Clinical improvement and survival in breast cancer leptomeningeal metastasis correlate with the cytologic response to intrathecal chemotherapy, J Neurooncol, vol.95, pp.421-426, 2009.

J. W. Hyun, I. H. Jeong, and A. Joung, Leptomeningeal metastasis: clinical experience of 519 cases, Eur J Cancer, vol.56, pp.107-114, 2016.

R. Boyle, M. Thomas, and J. H. Adams, Diffuse involvement of the leptomeninges by tumour-a clinical and pathological study of 63 cases, Postgrad Med J, vol.56, pp.149-158, 1980.

J. C. Gonzalez-vitale, R. Garcia-bunuel, and . Carcinomatosis, Cancer, vol.37, pp.2906-2911, 1976.

C. P. Kokkoris, Leptomeningeal carcinomatosis. How does cancer reach the pia-arachnoid?, Cancer, vol.51, pp.154-160, 1983.

H. V. Küsters-vandevelde, B. Küsters, and A. C. Van-engen-van-grunsven, Primary melanocytic tumors of the central nervous system: a review with focus on molecular aspects, Brain Pathol, vol.25, pp.209-226, 2015.

J. Kwon, E. K. Chie, and K. Kim, Impact of multimodality approach for patients with leptomeningeal metastases from solid tumors, J Korean Med Sci, vol.29, pp.1094-1101, 2014.

L. Nayak, L. M. Deangelis, and A. A. Brandes, The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria, Neuro Oncol, vol.19, pp.625-635, 2017.

M. Chamberlain, R. Soffietti, and J. Raizer, Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials, Neuro Oncol, vol.16, pp.1176-1185, 2014.

R. J. Freilich, G. Krol, and L. M. Deangelis, Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis, Ann Neurol, vol.38, pp.51-57, 1995.

S. K. Singh, J. M. Agris, N. E. Leeds, and L. E. Ginsberg, Intracranial leptomeningeal metastases: comparison of depiction at FLAIR and contrastenhanced MR imaging, Radiology, vol.217, pp.50-53, 2000.

C. S. Straathof, H. G. De-bruin, D. W. Dippel, and C. J. Vecht, The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis, J Neurol, vol.246, pp.810-814, 1999.

R. Zeiser, J. A. Burger, and T. A. Bley, Clinical follow-up indicates differential accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal fluid for the diagnosis of neoplastic meningitis-a single centre experience, Br J Haematol, vol.124, pp.762-768, 2004.

S. K. Singh, N. E. Leeds, and L. E. Ginsberg, MR imaging of leptomeningeal metastases: comparison of three sequences, AJNR Am J Neuroradiol, vol.23, pp.817-821, 2002.

G. Mahendru and V. Chong, Meninges in cancer imaging, Spec No A:S14-S21, vol.9, 2009.

G. Lombardi, F. Zustovich, and P. Farina, Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches, Oncologist, vol.16, pp.1175-1188, 2011.

S. A. Grossman, D. L. Trump, and D. C. Chen, Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography, Am J Med, vol.73, pp.641-647, 1982.

M. J. Glantz, W. A. Hall, and B. F. Cole, Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status, Cancer, vol.75, pp.2919-2931, 1995.

M. J. Glantz, B. F. Cole, and L. K. Glantz, Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results, Cancer, vol.82, pp.733-739, 1998.

L. R. Rogers, P. M. Duchesneau, and C. Nunez, Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis, Neurology, vol.42, pp.1239-1241, 1992.

R. Dux, A. Kindler-röhrborn, and M. Annas, A standardized protocol for flow cytometric analysis of cells isolated from cerebrospinal fluid, J Neurol Sci, vol.121, pp.74-78, 1994.

Z. Pan, G. Yang, and Y. Wang, Thinprep plus Papanicolaou stain method is more sensitive than cytospin-coupled Wright Giems stain method in cerebrospinal fluid cytology for diagnosis of leptomeningeal metastasis from solid tumors, PLoS One, vol.10, p.122016, 2015.

S. Quijano, A. , M. Sancho, and J. , Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry, J Clin Oncol, vol.27, pp.1462-1469, 2009.

A. S. Patel, J. E. Allen, and D. T. Dicker, Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases, Oncotarget, vol.2, pp.752-760, 2011.

E. Le-rhun, F. Massin, and Q. Tu, Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis, BMC Clin Pathol, vol.12, p.21, 2012.

J. S. Lee, M. E. Melisko, and M. J. Magbanua, Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer, Breast Cancer Res Treat, vol.154, pp.339-349, 2015.

B. Milojkovic-kerklaan, D. Pluim, and M. Bol, EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors, Neuro Oncol, vol.18, pp.855-862, 2016.

C. Ma, Y. Lv, and R. Jiang, Novel method for the detection and quantification of malignant cells in the CSF of patients with leptomeningeal metastasis of lung cancer, Oncol Lett, vol.11, pp.619-623, 2016.

D. Subir-a, S. O. , and M. , Diagnostic and prognostic significance of flow cytometry immunophenotyping in patients with leptomeningeal carcinomatosis, Clin Exp Metastasis, vol.32, pp.383-391, 2015.

Q. Tu, X. Wu, L. Rhun, and E. , CellSearch technology applied to the detection and quantification of tumor cells in CSF of patients with lung cancer leptomeningeal metastasis, Lung Cancer, vol.90, pp.352-357, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02939544

M. J. Magbanua, R. Roy, and E. V. Sosa, Genome-wide copy number analysis of cerebrospinal fluid tumor cells and their corresponding archival primary tumors, Genomics Data, vol.2, pp.60-62, 2014.

Y. Li, W. Pan, and C. Id, Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases, J Neurooncol, vol.128, pp.93-100, 2016.

S. Sasaki, Y. Yoshioka, and R. Ko, Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure, Respir Investig, vol.54, pp.14-19, 2016.

M. Shingyoji, H. Kageyama, and T. Sakaida, Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis, J Thorac Oncol, vol.6, pp.1215-1220, 2011.

H. Yang, L. Cai, and Y. Zhang, Sensitive detection of EGFR mutations in cerebrospinal fluid from lung adenocarcinoma patients with brain metastases, J Mol Diagn, vol.16, issue.5, pp.558-563, 2014.

E. Le-rhun, . Rud-a-r, and P. Devos, Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe, J Neuro-Oncol, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02940545

W. M. Pardridge and . Csf, blood-brain barrier, and brain drug delivery, Expert Opin Drug Deliv, vol.13, pp.963-975, 2016.

W. Boogerd, M. J. Van-den-bent, and P. J. Koehler, The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study, Eur J Cancer, vol.40, pp.2726-2733, 2004.

M. J. Glantz, B. F. Cole, and L. Recht, High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?, J Clin Oncol, vol.16, pp.1561-1567, 1998.

F. Bokstein, A. Lossos, and T. Siegal, Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy, Cancer, vol.82, pp.1756-1763, 1998.

R. Soffietti, U. Abacioglu, and B. Baumert, Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO), Neuro Oncol, vol.19, pp.162-174, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02940525

D. N. Church, R. Modgil, and S. Guglani, Extended survival in women with brain metastases from HER2 overexpressing breast cancer, Am J Clin Oncol, vol.31, pp.250-254, 2008.

A. M. Brufsky, M. Mayer, and H. S. Rugo, Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER, Clin Cancer Res, vol.17, pp.4834-4843, 2011.

N. U. Lin, L. A. Carey, and M. C. Liu, Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer, J Clin Oncol, vol.26, pp.1993-1999, 2008.

N. U. Lin, V. Diéras, and D. Paul, Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer, Clin Cancer Res, vol.15, pp.1452-1459, 2009.

M. Toi, H. Iwata, and Y. Fujiwara, Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies, Br J Cancer, vol.101, pp.1676-1682, 2009.

T. Bachelot, G. Romieu, and M. Campone, Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study, Lancet Oncol, vol.14, pp.64-71, 2013.

G. Metro, J. Foglietta, and M. Russillo, Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine, Ann Oncol, vol.22, pp.625-630, 2011.

S. Sutherland, S. Ashley, and D. Miles, Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases-the UK experience, Br J Cancer, vol.102, pp.995-1002, 2010.

R. Bartsch, A. S. Berghoff, and U. Vogl, Activity of T-DM1 in Her2-positive breast cancer brain metastases, Clin Exp Metastasis, vol.32, pp.729-737, 2015.

K. C. Keith, Y. Lee, and M. G. Ewend, Activity of trastuzumab-emtansine (TDM1) in HER2-positive breast cancer brain metastases: a case series, Cancer Treat Commun, vol.7, pp.43-46, 2016.

W. Jacot, E. Pons, and J. S. Frenel, Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases, Breast Cancer Res Treat, vol.157, pp.307-318, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02296735

S. Dudani, S. Mazzarello, and J. Hilton, Optimal management of leptomeningeal carcinomatosis in breast cancer patients-a systematic review, Clin Breast Cancer, vol.16, pp.456-470, 2016.

I. H. Park, Y. Kwon, and J. Y. Ro, Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue, Breast Cancer Res Treat, vol.123, pp.125-128, 2010.

P. F. Wu, C. H. Lin, and C. H. Kuo, A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis, BMC Cancer, vol.15, p.299, 2015.

M. Li, Q. Zhang, and P. Fu, Pemetrexed plus platinum as the firstline treatment option for advanced non-small cell lung cancer: a metaanalysis of randomized controlled trials, PLoS One, vol.7, p.37229, 2012.

S. Zimmermann, R. Dziadziuszko, and S. Peters, Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases, Cancer Treat Rev, vol.40, pp.716-722, 2014.

B. Besse, L. Moulec, S. Mazières, and J. , Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase II study, Clin Cancer Res, vol.21, pp.1896-1903, 2015.

F. Barlesi, J. Mazieres, and J. P. Merlio, Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), Lancet, vol.387, pp.1415-1426, 2016.

S. Umemura, K. Tsubouchi, and H. Yoshioka, Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group, Lung Cancer, vol.77, pp.134-139, 2012.

T. Kawamura, A. Hata, and J. Takeshita, High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs, Cancer Chemother Pharmacol, vol.75, pp.1261-1266, 2015.

D. M. Jackman, L. A. Cioffredi, and L. Jacobs, A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer, Oncotarget, vol.6, pp.4527-4536, 2015.

S. Tetsumoto, A. Osa, and T. Kijima, Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib, Int J Clin Oncol, vol.17, pp.155-159, 2012.

P. Hoffknecht, A. Tufman, and T. Wehler, Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease, J Thorac Oncol, vol.10, pp.156-163, 2015.

T. S. Mok, Y. Wu, and M. Ahn, Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer, N Engl J Med, vol.376, pp.629-640, 2017.

Y. Togashi, K. Masago, and S. Masuda, Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer, Cancer Chemother Pharmacol, vol.70, pp.399-405, 2012.

J. Yang, D. W. Kim, and S. W. Kim, Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study, J Clin. Oncol, vol.34, p.9002, 2016.

B. J. Solomon, F. Cappuzzo, and E. Felip, Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014, J Clin Oncol, vol.34, pp.2858-2865, 2016.

I. Zhang, N. G. Zaorsky, and J. D. Palmer, Targeting brain metastases in ALKrearranged non-small-cell lung cancer, Lancet Oncol, vol.16, pp.510-521, 2015.

J. Brahmer, K. L. Reckamp, and P. Baas, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, vol.373, pp.123-135, 2015.

H. Borghaei, L. Paz-ares, and L. Horn, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, vol.373, pp.1627-1639, 2015.

R. S. Herbst, P. Baas, and D. W. Kim, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, vol.387, pp.1540-1550, 2016.

A. Rittmeyer, F. Barlesi, A. Rittmeyer, F. Barlesi, and D. Waterkamp, Atezolizumab versus docetaxel in patients with previously treated nonsmall-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet, vol.389, pp.255-265, 2017.

S. B. Goldberg, S. N. Gettinger, and A. Mahajan, Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial, Lancet Oncol, vol.17, pp.976-983, 2016.

K. Margolin, M. S. Ernstoff, and O. Hamid, Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial, Lancet Oncol, vol.13, pp.459-465, 2012.

M. P. Konstantinou, C. Dutriaux, and C. Gaudy-marqueste, Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients, Acta Derm Venereol, vol.94, pp.45-49, 2014.

G. T. Gibney, P. A. Forsyth, and V. K. Sondak, Melanoma in the brain: biology and therapeutic options, Melanoma Res, vol.22, pp.177-183, 2012.

R. Dummer, S. M. Goldinger, and C. P. Turtschi, Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study, Eur J Cancer, vol.50, pp.611-621, 2014.

F. Fennira, C. Pagès, and P. Schneider, Vemurafenib in the French temporary authorization for use metastatic melanoma cohort: a singlecentre trial, Melanoma Res, vol.24, pp.75-82, 2014.

G. V. Long, U. Trefzer, and M. A. Davies, Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial, Lancet Oncol, vol.13, pp.1087-1095, 2012.

T. Siegal, Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy?, J Neurooncol, vol.38, pp.151-157, 1998.

A. B. Lassman, L. E. Abrey, and G. D. Shah, Systemic high-dose intravenous methotrexate for central nervous system metastases, J Neurooncol, vol.78, pp.255-260, 2006.

J. Chahal, A. Stopeck, and K. Clarke, Intravenous thiotepa for treatment of breast cancer-related leptomeningeal carcinomatosis: case series, Neurol Sci, vol.36, pp.1691-1693, 2015.

J. C. Benjamin, T. Moss, and R. P. Moseley, Cerebral distribution of immunoconjugate after treatment for neoplastic meningitis using an intrathecal radiolabeled monoclonal antibody, Neurosurgery, vol.25, pp.253-258, 1989.

P. A. Burch, S. A. Grossman, and C. S. Reinhard, Spinal cord penetration of intrathecally administered cytarabine and methotrexate: a quantitative autoradiographic study, J Natl Cancer Inst, vol.80, pp.1211-1216, 1988.

S. M. Blaney, D. E. Cole, and K. Godwin, Intrathecal administration of topotecan in nonhuman primates, Cancer Chemother Pharmacol, vol.36, pp.121-124, 1995.

M. J. Glantz, A. Van-horn, R. Fisher, and M. C. Chamberlain, Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis, Cancer, vol.116, pp.1947-1952, 2010.

W. R. Shapiro, M. Schmid, M. Glantz, and J. J. Miller, A randomized phase III/ IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis, J Clin Oncol, vol.24, p.1528, 2006.

F. Zairi, L. Rhun, E. Bertrand, and N. , Complications related to the use of an intraventricular access device for the treatment of leptomeningeal metastases from solid tumor: a single centre experience in 112 patients, J Neurooncol, vol.124, pp.317-323, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02939512

B. C. Kennedy, L. T. Brown, R. J. Komotar, and G. M. Mckhann, Stereotactic catheter placement for Ommaya reservoirs, J Clin Neurosci, vol.27, pp.44-47, 2016.

P. F. Morgenstern, S. Connors, A. S. Reiner, and J. P. Greenfield, Image guidance for placement of Ommaya reservoirs: comparison of fluoroscopy and frameless stereotactic navigation in 145 patients, World Neurosurg, vol.93, pp.154-158, 2016.

H. S. Gwak, J. Joo, and S. H. Shin, Ventriculolumbar perfusion chemotherapy with methotrexate for treating leptomeningeal carcinomatosis: a Phase II Study, Oncologist, vol.19, pp.1044-1045, 2014.

S. A. Grossman, D. M. Finkelstein, and J. C. Ruckdeschel, Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group, J Clin Oncol, vol.11, pp.561-569, 1993.

M. J. Glantz, K. A. Jaeckle, and M. C. Chamberlain, A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors, Clin Cancer Res, vol.5, pp.3394-3402, 1999.

R. N. Hitchins, D. R. Bell, R. L. Woods, and J. A. Levi, A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis, J Clin Oncol, vol.5, pp.1655-1662, 1987.

B. F. Cole, M. J. Glantz, and K. A. Jaeckle, Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis, Cancer, vol.97, pp.3053-3060, 2003.

F. Zagouri, T. N. Sergentanis, and R. Bartsch, Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis, Breast Cancer Res Treat, vol.139, pp.13-22, 2013.

M. C. Chamberlain and P. A. Kormanik, Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases, Neurology, vol.46, pp.1674-1677, 1996.

M. C. Chamberlain, Radioisotope CSF flow studies in leptomeningeal metastases, J Neurooncol, vol.38, pp.135-140, 1998.

Z. Pan, G. Yang, and H. He, Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: a prospective and single-arm study, Int J Cancer, vol.139, pp.1864-1872, 2016.

M. C. Chamberlain and S. K. Johnston, Neoplastic meningitis: survival as a function of cerebrospinal fluid cytology, Cancer, vol.115, pp.1941-1946, 2009.

M. Weller, R. Stupp, and W. Wick, Epilepsy meets cancer: when, why, and what to do about it, Lancet Oncol, vol.13, pp.375-382, 2012.

I. W. Tremont-lukats, B. O. Ratilal, T. Armstrong, and M. R. Gilbert, Antiepileptic drugs for preventing seizures in people with brain tumors, Cochrane Database Syst Rev, vol.004424, 2008.

T. Y. Jung, W. K. Chung, and I. J. Oh, The prognostic significance of surgically treated hydrocephalus in leptomeningeal metastases, Clin Neurol Neurosurg, vol.119, pp.80-83, 2014.

F. Nigim, J. F. Critchlow, and E. M. Kasper, Role of ventriculoperitoneal shunting in patients with neoplasms of the central nervous system: an analysis of 59 cases, Mol Clin Oncol, vol.3, pp.1381-1386, 2015.

X. H. Zhang, X. G. Wang, and Y. Z. Piao, Lumboperitoneal shunt for the treatment of leptomeningeal metastasis, Med Hypotheses, vol.84, pp.506-508, 2015.

S. Yamashiro, Y. Hitoshi, and S. Tajiri, Palliative lumboperitoneal shunt for leptomeningeal metastasis-related hydrocephalus: a case series, Palliat Med, vol.31, pp.93-96, 2017.

A. Pace, L. Dirven, L. Koekkoek, and J. , on behalf of the European Association of Neuro-Oncology palliative care task force. EANO guidelines for palliative care in adult glioma patients, Lancet Oncol, vol.18, pp.330-340, 2017.

M. Brainin, M. Barnes, and J. C. Baron, Guidance for the preparation of neurological management guidelines by EFNS scientific task forcesrevised recommendations, Eur J Neurol, vol.11, pp.577-581, 2004.

C. A. Dykewicz, Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients, Clin Infect Dis, vol.33, pp.139-144, 2001.